Josh Schimmer
Stock Analyst at Cantor Fitzgerald
(4.39)
# 354
Out of 5,122 analysts
147
Total ratings
54.55%
Success rate
17.31%
Average return
Main Sectors:
Stocks Rated by Josh Schimmer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MIRM Mirum Pharmaceuticals | Maintains: Overweight | $95 → $130 | $103.25 | +25.91% | 7 | Dec 8, 2025 | |
| JANX Janux Therapeutics | Maintains: Overweight | $200 → $150 | $13.23 | +1,033.79% | 7 | Dec 2, 2025 | |
| DMAC DiaMedica Therapeutics | Initiates: Overweight | $25 | $7.90 | +216.46% | 1 | Nov 14, 2025 | |
| PVLA Palvella Therapeutics | Maintains: Overweight | $120 → $200 | $83.40 | +139.81% | 1 | Nov 6, 2025 | |
| CABA Cabaletta Bio | Maintains: Overweight | $15 → $30 | $2.52 | +1,090.48% | 3 | Oct 31, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Overweight | $100 → $110 | $75.77 | +45.18% | 13 | Oct 30, 2025 | |
| NUVL Nuvalent | Initiates: Overweight | $135 | $108.59 | +24.32% | 1 | Oct 15, 2025 | |
| IVVD Invivyd | Initiates: Overweight | $10 | $1.85 | +440.54% | 1 | Oct 6, 2025 | |
| RNA Avidity Biosciences | Maintains: Outperform | $70 → $65 | $72.74 | -10.64% | 6 | Sep 22, 2025 | |
| CGON CG Oncology | Reiterates: Overweight | $75 | $51.75 | +44.93% | 5 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $20.75 | - | 3 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $25 | $24.66 | +1.38% | 4 | Sep 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 → $8 | $3.31 | +141.69% | 7 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $25 | $11.80 | +111.86% | 1 | Jul 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $11 → $6 | $6.27 | -4.31% | 2 | Jun 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $260 → $280 | $220.18 | +27.17% | 4 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $12.47 | +300.96% | 2 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $20 | $3.97 | +403.78% | 2 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $215 | $270.04 | -20.38% | 5 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $5 | $2.44 | +104.92% | 4 | Dec 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $6.09 | - | 5 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $30 | $10.16 | +195.42% | 4 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $9.52 | - | 3 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.85 | - | 2 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $90 | $47.55 | +89.27% | 6 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.36 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $155.94 | - | 5 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $68.85 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $7.41 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $6.15 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $70.33 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 | $0.59 | +2,455.37% | 3 | Aug 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $65 | $41.24 | +57.63% | 3 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $43 → $5 | $13.92 | -64.08% | 2 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $11 | $11.75 | -6.38% | 2 | Jun 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $140 → $130 | $139.13 | -6.56% | 1 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $760 | $785.34 | -3.23% | 2 | Oct 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $15 | $23.36 | -35.79% | 1 | Mar 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $55 | $12.39 | +343.91% | 1 | Feb 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $1.52 | +1,873.68% | 1 | Dec 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | n/a | $1.02 | - | 4 | Dec 9, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $11.04 | - | 3 | Feb 25, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $222 → $250 | $486.88 | -48.65% | 4 | Nov 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $105.97 | - | 2 | Jun 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | n/a | $86.39 | - | 2 | May 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | n/a | $3.75 | - | 2 | Mar 12, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $22 | $26.97 | -18.43% | 1 | Nov 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $20.36 | - | 2 | Aug 17, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $57.65 | - | 1 | Aug 17, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $95 | $216.38 | -56.09% | 1 | Aug 17, 2017 |
Mirum Pharmaceuticals
Dec 8, 2025
Maintains: Overweight
Price Target: $95 → $130
Current: $103.25
Upside: +25.91%
Janux Therapeutics
Dec 2, 2025
Maintains: Overweight
Price Target: $200 → $150
Current: $13.23
Upside: +1,033.79%
DiaMedica Therapeutics
Nov 14, 2025
Initiates: Overweight
Price Target: $25
Current: $7.90
Upside: +216.46%
Palvella Therapeutics
Nov 6, 2025
Maintains: Overweight
Price Target: $120 → $200
Current: $83.40
Upside: +139.81%
Cabaletta Bio
Oct 31, 2025
Maintains: Overweight
Price Target: $15 → $30
Current: $2.52
Upside: +1,090.48%
BridgeBio Pharma
Oct 30, 2025
Maintains: Overweight
Price Target: $100 → $110
Current: $75.77
Upside: +45.18%
Nuvalent
Oct 15, 2025
Initiates: Overweight
Price Target: $135
Current: $108.59
Upside: +24.32%
Invivyd
Oct 6, 2025
Initiates: Overweight
Price Target: $10
Current: $1.85
Upside: +440.54%
Avidity Biosciences
Sep 22, 2025
Maintains: Outperform
Price Target: $70 → $65
Current: $72.74
Upside: -10.64%
CG Oncology
Sep 8, 2025
Reiterates: Overweight
Price Target: $75
Current: $51.75
Upside: +44.93%
Sep 8, 2025
Reiterates: Overweight
Price Target: n/a
Current: $20.75
Upside: -
Sep 5, 2025
Reiterates: Overweight
Price Target: $25
Current: $24.66
Upside: +1.38%
Aug 8, 2025
Maintains: Overweight
Price Target: $10 → $8
Current: $3.31
Upside: +141.69%
Jul 1, 2025
Initiates: Overweight
Price Target: $25
Current: $11.80
Upside: +111.86%
Jun 23, 2025
Downgrades: In-Line
Price Target: $11 → $6
Current: $6.27
Upside: -4.31%
May 2, 2025
Maintains: Outperform
Price Target: $260 → $280
Current: $220.18
Upside: +27.17%
Apr 1, 2025
Reiterates: Overweight
Price Target: $50
Current: $12.47
Upside: +300.96%
Mar 25, 2025
Maintains: Overweight
Price Target: $23 → $20
Current: $3.97
Upside: +403.78%
Feb 20, 2025
Reiterates: Overweight
Price Target: $215
Current: $270.04
Upside: -20.38%
Dec 20, 2024
Downgrades: In-Line
Price Target: $5
Current: $2.44
Upside: +104.92%
Dec 11, 2024
Reiterates: Overweight
Price Target: n/a
Current: $6.09
Upside: -
Oct 8, 2024
Reiterates: Overweight
Price Target: $30
Current: $10.16
Upside: +195.42%
Sep 23, 2024
Downgrades: Neutral
Price Target: n/a
Current: $9.52
Upside: -
Sep 17, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.85
Upside: -
Sep 16, 2024
Reiterates: Overweight
Price Target: $90
Current: $47.55
Upside: +89.27%
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.36
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $155.94
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $68.85
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $7.41
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $6.15
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $70.33
Upside: -
Aug 26, 2024
Maintains: Outperform
Price Target: $15
Current: $0.59
Upside: +2,455.37%
Aug 9, 2024
Reiterates: Overweight
Price Target: $65
Current: $41.24
Upside: +57.63%
Nov 10, 2023
Downgrades: In-Line
Price Target: $43 → $5
Current: $13.92
Upside: -64.08%
Jun 6, 2023
Maintains: Outperform
Price Target: $20 → $11
Current: $11.75
Upside: -6.38%
Nov 14, 2022
Downgrades: In-Line
Price Target: $140 → $130
Current: $139.13
Upside: -6.56%
Oct 17, 2022
Downgrades: In-Line
Price Target: $760
Current: $785.34
Upside: -3.23%
Mar 15, 2022
Initiates: Outperform
Price Target: $15
Current: $23.36
Upside: -35.79%
Feb 2, 2021
Initiates: Outperform
Price Target: $55
Current: $12.39
Upside: +343.91%
Dec 29, 2020
Initiates: Outperform
Price Target: $30
Current: $1.52
Upside: +1,873.68%
Dec 9, 2019
Downgrades: In-Line
Price Target: n/a
Current: $1.02
Upside: -
Feb 25, 2019
Upgrades: Outperform
Price Target: n/a
Current: $11.04
Upside: -
Nov 16, 2018
Upgrades: Outperform
Price Target: $222 → $250
Current: $486.88
Upside: -48.65%
Jun 11, 2018
Upgrades: Outperform
Price Target: n/a
Current: $105.97
Upside: -
May 8, 2018
Downgrades: In-Line
Price Target: n/a
Current: $86.39
Upside: -
Mar 12, 2018
Downgrades: In-Line
Price Target: n/a
Current: $3.75
Upside: -
Nov 7, 2017
Initiates: Outperform
Price Target: $22
Current: $26.97
Upside: -18.43%
Aug 17, 2017
Initiates: Outperform
Price Target: n/a
Current: $20.36
Upside: -
Aug 17, 2017
Initiates: Outperform
Price Target: n/a
Current: $57.65
Upside: -
Aug 17, 2017
Initiates: Outperform
Price Target: $95
Current: $216.38
Upside: -56.09%